Korro Bio, Inc.

Korro Bio, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • KRRO (NCM)

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

617 468 1999 One Kendall Square, Cambridge, MA 02139, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Korro Bio Plummets To A Record Low On A Big Setback In RNA Editing - Investor's Business Daily
Investor's Business Daily • Nov 13
Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot - Yahoo Finance
Yahoo Finance • Nov 14
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia - Genetic Engineering and Biotechnology News
Genetic Engineering and Biotechnology News • Nov 16
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal - BioSpace
BioSpace • Nov 13
Korro Bio stock plummets after mixed AATD trial results - Investing.com
Investing.com • Nov 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Korro Bio, Inc. had layoffs?
No layoff events have been recorded for Korro Bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Korro Bio, Inc. have?
Korro Bio, Inc. has approximately 87 employees.
What industry is Korro Bio, Inc. in?
Korro Bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Korro Bio, Inc. a publicly traded company?
Yes, Korro Bio, Inc. is publicly traded under the ticker symbol KRRO on the NCM. The company has a market capitalization of approximately $0.08 billion.
Where is Korro Bio, Inc. headquartered?
Korro Bio, Inc. is headquartered in Cambridge, MA, United States at One Kendall Square, Cambridge, MA 02139, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.